New Analysis Of REMICADE For UC In Patients With Recent Disease Onset Or Long-Standing Disease

Data from a new analysis of the Active Ulcerative Colitis Trials (ACT 1 and ACT 2) showed that at week 8, more than 60 percent of patients with moderately to severely active ulcerative colitis (UC) receiving REMICADE® (infliximab) achieved clinical response regardless of disease duration (less than three years versus at least three years).

More: continued here

Filed under: Clinical Trials on May 22nd, 2008